Showing results (1-10 of 47) with videos related to
Sort By:
Pageof 5
Clinical Science (London, England : 1979)|September 25, 2013
microRNA in the development of diabetic complicationsAaron D McClelland, Phillip KantharidisKidney International|January 5, 2024
YB-1: the Jekyll and Hyde of kidney disease?Phillip Kantharidis, Mark E CooperJournal of Diabetes Research|February 28, 2014
MicroRNA in diabetic nephropathy: renin angiotensin, aGE/RAGE, and oxidative stress pathwayShinji Hagiwara, Aaron McClelland, Phillip KantharidisCurrent Opinion in Nephrology and Hypertension|November 20, 2013
Where are we in diabetic nephropathy: microRNAs and biomarkers?Aaron McClelland, Shinji Hagiwara, Phillip KantharidisCurrent Pharmaceutical Design|July 13, 2013
MicroRNA as biomarkers and regulator of cardiovascular development and diseaseShinji Hagiwara, Phillip Kantharidis, Mark E CooperCell and Tissue Research|August 17, 2011
The role of EMT in renal fibrosisRosemarie M Carew, Bo Wang, Phillip KantharidisCurrent Hypertension Reports|February 3, 2012
What are new avenues for renal protection, in addition to RAAS inhibition?Shinji Hagiwara, Phillip Kantharidis, Mark E CooperMethods in Molecular Biology (Clifton, N.J.)|January 17, 2009
Quantitative gene expression analysis in kidney tissuesChris Tikellis, Philip Koh, Wendy Burns, et al.Nephrology (Carlton, Vic.)|December 10, 2014
Study of microRNA in diabetic nephropathy: isolation, quantification and biological functionPhillip Kantharidis, Shinji Hagiwara, Eoin Brennan, et al.Nature Reviews. Nephrology|July 20, 2021
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney functionEoin Brennan, Phillip Kantharidis, Mark E Cooper, et al.Pageof 5